Search the Newsreel

Beamr Imaging Ltd (BMR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Beamr Imaging Ltd (BMR), detailing analyst ratings and target prices. Based on one analyst, the stock has a "Buy" rating with a target price of USD 8.00, representing a significant upside. The current stock price and market …

Noticias de acciones de Beam Therapeutics Inc (BEAM)

Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results

Analysts have lowered their revenue expectations for Beam Therapeutics (NASDAQ:BEAM) after the company reported second-quarter results that fell short of estimates. While revenue forecasts for 2026 were significantly cut, loss per share estimates remained steady, and the average price target did not change, suggesting …

First Trust Advisors LP Increases Stock Position in Beam Therapeutics Inc. $BEAM

Nvidia Video Super Resolution for Beamr

Beamr Imaging is partnering with Nvidia to bring AI upscaling to live sports, broadcast, and streaming content using Nvidia Video Super Resolution combined with Beamr’s content-adaptive bitrate (CABR) encoding. This collaboration aims to deliver 4K viewing experiences from existing HD feeds at significantly reduced …

Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

Beam Therapeutics, Inc. (NASDAQ: BEAM) had approximately 517 employees worldwide as of March 2026, marking a 2.3% decline from 530 employees in 2023. Despite this overall decline, the company is actively hiring, with 71 active job postings in 2026, a 42.7% increase from 2025. …

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Beam Therapeutics (BEAM) reported a wider-than-expected loss of $1.18 per share in Q2 2026, missing the Zacks Consensus Estimate of a $1.00 loss, and revenues fell significantly year-over-year. Despite the financial performance, the company is advancing its pipeline, including candidates for sickle cell disease …

How Beam’s Wider Q2 Loss and Trial Progress Will Impact Beam Therapeutics (BEAM) Investors

Beam Therapeutics reported a wider net loss of US$122.68 million and a revenue shortfall in Q2 2026, yet achieved key clinical milestones including completing dosing for its risto-cel sickle cell trial and dosing the first patient in the BEAM-302 study. The article discusses how …

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine, Inc. -- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable arbitration resolution with Beam Therapeutics …

Beam Global deploys EV charging systems in Serbia's Vrnjacka Banja

Beam Global has deployed EV charging systems in Vrnjacka Banja, Serbia. This initiative represents an investment in the country's automotive and engineering industries. The deployment highlights the growing focus on electric vehicle infrastructure in Southeast Europe.

BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM)

HeartBeam, Inc. (BEATW) Analyst insights, Price targets and Recommendations

The article provides analyst insights, price targets, and recommendations for HeartBeam, Inc. (BEATW). It includes current stock performance, related tickers, and general market data. The stock BEATW is shown to be trading at $0.0150, down 30.23% at market close on August 7.

Price to earnings forward of Heartbeam, Inc. – NASDAQ:BEATW

This article provides financial information for Heartbeam, Inc. (NASDAQ:BEATW), specifically focusing on its Price to Earnings (forward) metric. It is presented through TradingView, noting that the market is currently closed with no trades. The content highlights the company's financial data and general market information …

Price to sales forward of Heartbeam, Inc. – NASDAQ:BEATW

This page from TradingView provides a financial overview for Heartbeam, Inc. (NASDAQ: BEATW), specifically focusing on its Price to Sales (forward) metric. The content lists various navigation options and product offerings by TradingView, but the core financial data regarding Heartbeam, Inc.'s price to sales …

Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside

Analysts have cut the average 12-month price target for Beam Therapeutics Inc. (BEAM) stock from $51.36 to $51.07, with individual forecasts ranging from $26 to $80 per share. This updated target suggests an 80% potential upside based on the Aug. 4 closing price. The …

Beam Therapeutics (BEAM) On A Wider Q2 Loss And The Valuation Debate

Beam Therapeutics (BEAM) reported a wider net loss and higher loss per share for Q2 2026, yet saw a short-term share price bounce. Despite a challenging longer-term stock performance, a "Most Popular Narrative" suggests the company is 44.5% undervalued with a fair value of …

Beamr Turns HD Sports Feeds Into 4K Streams Up to 50% Smaller

Beamr (Nasdaq: BMR) has integrated NVIDIA Video Super Resolution with its content-adaptive bitrate (CABR) encoding to enable AI-based 4K upscaling for live sports and broadcast. This technology allows existing HD feeds to be converted into a 4K viewing experience while reducing stream sizes by …

Beamr Imaging Ltd. (Nasdaq: BMR) adds NVIDIA AI upscaling for 4K sports

Beamr Imaging Ltd. announced a new integration of NVIDIA Video Super Resolution into its workflows, combining it with Beamr's content-adaptive bitrate (CABR) encoding. This solution aims to provide AI upscaling for live sports, broadcast, and streaming, converting existing HD feeds into a 4K viewing …

A Serbian Spa Gets 100% Renewable EV Charging Off Grid

Beam Global has deployed its EV ARC off-grid EV charging systems at Aqua Park Raj in Vrnjačka Banja, Serbia, under a recurring revenue agreement. These solar-powered units provide 100% renewable charging without grid connection, aiming to enhance guest experience and support Serbia’s EU Green …

Beam Global Expands Recurring Revenue, Sponsorship Funded, EV ARC™ Deployments in Serbia

Beam Global has deployed EV ARC™ off-grid electric vehicle charging systems at Aqua Park Raj in Serbia under a recurring revenue agreement, marking a significant step in its European expansion. This deployment enables zero upfront cost EV charging for the park, leveraging sponsorship models …

Beam Communications (ASX:BCC) Firms as Zoleo Proceeds Reset the Balance Sheet

Enterprise value to revenue forward of Heartbeam, Inc. – NASDAQ:BEATW

This article focuses on the enterprise value to revenue forward metric for Heartbeam, Inc. (NASDAQ:BEATW). It indicates that the company's financial data for this specific metric is available. The article is a financial data point from TradingView.

Beam Therapeutics completes dosing in sickle cell trial

Beam Therapeutics announced the completion of dosing for adult and adolescent patients in its Phase 1/2 BEACON trial for sickle cell disease, with a biologics license application expected by late 2026 and updated data by year-end. The company also reported progress in other trials, …

Beam Global supplies EV ARC off-grid charging systems for Dallas municipal fleet and Massachusetts carshare pilot

Beam Global has secured a follow-on order from the city of Dallas for ten EV ARC systems to support its municipal EV fleet, marking the city's fourth purchase since 2025. Concurrently, Beam Global's EV ARC systems are being utilized in Boston's Metropolitan Area Planning …

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago. These figures are adjusted for non-recurring items. This …

Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans

Beam Therapeutics reported a Q2 2026 net loss of $122.7 million ($1.18 per share) on $490 thousand in license and collaboration revenue, ending the quarter with $1.2 billion in cash. The company expects this capital, plus an additional $200 million from a credit facility, …

Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $490,000, vs. FactSet Est of $16.4M

Beam Therapeutics Inc. reported Q2 revenue of $490,000, significantly missing the FactSet estimate of $16.4 million. The company also posted a Q2 loss of $1.18 per share, which was higher than the FactSet estimated loss of $1.11 per share. This financial update indicates a …

Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary

Beam Therapeutics Inc. reported its second-quarter 2026 results, showing a revenue of $0.5 million and a diluted loss per share of $(1.18). The company also highlighted clinical progress with its BEACON risto-cel program targeting a BLA filing by year-end 2026, advancing LNP programs, and …

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission …

Beam Therapeutics (NASDAQ:BEAM) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Beam Therapeutics (BEAM) Earnings Date and Reports 2026

CurveBeam AI launches discounted share purchase plan to bolster capital for imaging growth

Dimensional Fund Advisors LP Has $51.33 Million Stock Position in Beam Therapeutics Inc. $BEAM

Beamr Frozen on VISTA Launch

Beamr Imaging Ltd. (NASDAQ: BMR) launched VISTA, a managed platform for subjective video quality testing at scale, aiming to bridge the gap between fast but unreliable objective metrics and complex subjective lab tests. The company will demonstrate VISTA's application in validating NVIDIA RTX Video …

Heartbeam, Inc. Revenue Breakdown – NASDAQ:BEATW

This page provides financial overview and data for Heartbeam, Inc. under the NASDAQ:BEATW ticker. It details various financial segments, including statements, statistics, dividends, earnings, and allows users to explore revenue breakdown by source and country, though no specific financial figures are displayed in the …

Beam Therapeutics Inc (BEAM) Institutional Confidence

Beam Therapeutics Inc (BEAM) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding stands at 103.20%, a decrease of 9.85% quarter-over-quarter. Catherine Wood is the largest institutional shareholder, holding 9.07 million shares, which represents …